Three-year clinical outcomes of a sirolimus-eluting bioresorbable scaffold (XINSORB) and a metallic stent to treat coronary artery stenosis

Abstract

In this XINSORB randomized clinical trial, the XINSORB scaffolds and SESs showed similar efficacy and safety up to the 3-year follow-up. The rates of TLF and device thrombosis were low and comparable between the two arms.